Shares of Myovant Sciences MYOV rose 1.1% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were down 81.08% year over year to ($0.67), which missed the estimate of ($0.33).
Revenue of $41,063,000 higher by 23.19% from the same period last year, which missed the estimate of $57,050,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Jul 28, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/f72rq7tp
Technicals
Company's 52-week high was at $30.90
52-week low: $13.42
Price action over last quarter: down 0.82%
Company Overview
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.